Filing search / Current reports / Cullinan Oncology, Inc.

8-K

CGEM Cullinan Oncology, Inc.

16 Oct 24

CLN-978 is the first development stage CD19 T cell engager to receive U.S. FDA IND clearance in autoimmune diseases

7:17am

8-K

CGEM Cullinan Oncology, Inc.

17 Sep 24

Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus

7:13am

8-K

CGEM Cullinan Oncology, Inc.

8 Aug 24

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

7:15am

8-K

CGEM Cullinan Oncology, Inc.

27 Jun 24

Submission of Matters to a Vote of Security Holders

5:00pm

8-K

CGEM Cullinan Oncology, Inc.

3 Jun 24

Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib

8:12am

8-K

x22nkryu9i g1

23 May 24

Regulation FD Disclosure

5:07pm

8-K

rsgsj8k3wpitb qckqe

15 May 24

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

4:15pm

8-K

x3ikbhjk

29 Apr 24

Departure of Directors or Certain Officers

7:05am

8-K

tqncswam

16 Apr 24

Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement

7:14am

8-K

vw2ddl

14 Mar 24

Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

7:14am

8-K/A

xle t0g1hg

8 Jan 24

Results of Operations and Financial Condition

4:15pm

8-K

tc7qeyk9

8 Jan 24

Completion of Acquisition or Disposition of Assets

9:12am

8-K

l1ljl2q

8 Nov 23

Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results

7:10am

8-K

zqe856ulxpczo

10 Aug 23

Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results

7:07am

8-K

l57bzbbkgfjt8d

14 Jun 23

Departure of Directors or Certain Officers

4:15pm

8-K

i09rx5 1010uy8pr

25 May 23

Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-MICA/B Antibody, at ASCO 2023

5:05pm

8-K

ckwje t4rump

11 May 23

Cullinan Oncology Provides Corporate Update and Reports First Quarter 2023 Financial Results

4:09pm

8-K

qizcoksz4ujtqgx95fh

9 Mar 23

Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

7:11am

8-K

8rn7k1l ca

13 Feb 23

Cullinan Oncology Licenses U.S. Rights to the First Clinical-Stage B7H4 x 4-1BB

7:11pm

8-K

qnwd bdfums

19 Jan 23

Unregistered Sales of Equity Securities

4:40pm